Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin narrows to -93.9%

Net margin was -93.9% in Q1 FY2026, down 35.0 pp from a year earlier. On a trailing-twelve-month basis it was -110.0%, down 88.0 pp year over year. Over 3 fiscal years it narrowed by 104.5 pp.

Context

  • Net margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of -61.4% for the fiscal year ending Dec 2026, up from -102.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-93.9%+152.9 pp QoQ
Last fiscal yearDec 2025
-102.0%-92.5 pp YoY
LTMMar 2026
-110.0%-88.0 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-35.0 pp-5.1 pp+29.8 pp
1 year-92.5 pp+40.6 pp+133.1 pp
3 years-104.5 pp+89.6 pp+194.0 pp
5 years+107.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-102.0%
Year-over-year change
-92.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 net margin of -110.0% is the highest of the 5 companies compared; the peer median is -1607.3%.
  • Its year-over-year change of -88.0 pp is the highest of 5, against a peer median of -1551.3 pp.
  • Over three fiscal years its change of -104.5 pp compares with a peer median of -183.1 pp.
VNDA Competitors Peer median
Net Margin for VNDA and competitors
Company Period LTM level YoY 3-year change
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026-110.0% -88.0 pp-104.5 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-173.5% -123.0 pp-102.4 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-319.6% -193.1 pp-183.1 pp
TRDAEntrada Therapeutics, Inc.LTM Mar 2026-2895.1% -2909.4 pp—
HUMAHumacyte, Inc.LTM Mar 2026-4840.8% -3838.0 pp-1239.0 pp
ACHVAchieve Life Sciences, Inc.FY2025— ——
CAPRCapricor Therapeutics, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
SGMTSagimet Biosciences Inc.FY2025— ——
ALLOAllogene Therapeutics, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding VNDA) -1607.3%-1551.3 pp-183.1 pp

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.